Olaratumab (LY3012207) Patient Access for Soft Tissue Sarcoma
NCT ID: NCT03994627
Last Updated: 2024-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
APPROVED_FOR_MARKETING
EXPANDED_ACCESS
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Olaratumab
Administered intravenously (IV)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Have metastatic or locally advanced unresectable soft tissue sarcoma not amenable to curative treatment with surgery or radiotherapy.
* Have given written informed consent.
* Have an absolute neutrophil count (ANC) ≥1,000/microliter.
* Females of childbearing potential and males must agree to use highly effective contraceptive precautions during treatment with olaratumab and up to 3 months following the last dose of olaratumab. A highly effective method of birth control is defined as one that results in a low failure rate (that is, \<1% per year) when used consistently and correctly, such as implants, injectables, combined oral contraceptives, some intrauterine contraceptive devices (IUDs), sexual abstinence, or a vasectomized partner.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Eli Lilly and Company
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ironwood Cancer & Research Centers
Glendale, Arizona, United States
Marin Specialty Care, Inc
Greenbrae, California, United States
The Angeles Clinic & Research Institute
Los Angeles, California, United States
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California, United States
Kaiser Permanente West Los Angeles
Los Angeles, California, United States
Kaiser Permanente Moreno Valley
Moreno Valley, California, United States
University of Colorado Health Hospital
Aurora, Colorado, United States
UCHealth Cancer Center
Fort Collins, Colorado, United States
Baptist MD Anderson Cancer Center
Jacksonville, Florida, United States
Mayo Clinic in Florida
Jacksonville, Florida, United States
Ocala Oncology, P.A.
Ocala, Florida, United States
Florida Cancer Specialists
Orlando, Florida, United States
Orlando Health UF Health Cancer Center
Orlando, Florida, United States
Florida Cancer Specialists
Sarasota, Florida, United States
Oncology-Hematology Associates of West Broward
Tamarac, Florida, United States
Northside Hospital
Athens, Georgia, United States
Tift Regional Health System Anita Stewart Oncology Center
Tifton, Georgia, United States
Beacon Cancer Care
Coeur d'Alene, Idaho, United States
Rush University Medical Center
Chicago, Illinois, United States
Illinois Cancer Care
Peoria, Illinois, United States
Hematology Oncology Clinic
Baton Rouge, Louisiana, United States
Alton Ochsner Medical Center
New Orleans, Louisiana, United States
University of Maryland, Baltimore
Baltimore, Maryland, United States
SKCCC at Johns Hopkins
Baltimore, Maryland, United States
Baltimore Washington Health Services
Glen Burnie, Maryland, United States
University of Massachusetts Medical Center
Worcester, Massachusetts, United States
Henry Ford Macomb Hospital
Clinton Township, Michigan, United States
Cancer & Hematology Centers of Western Michigan
Grand Rapids, Michigan, United States
St. Luke's Hospital of Duluth
Duluth, Minnesota, United States
Masonic Cancer Center, University
Minneapolis, Minnesota, United States
Jackson Oncology Associates, PLLC
Jackson, Mississippi, United States
University of Mississippi School of Medicine
Jackson, Mississippi, United States
County Oncologist, Inc.
St Louis, Missouri, United States
Cooper Hospital University Medical Center
Camden, New Jersey, United States
Regional Cancer Care Associates, LLC
East Brunswick, New Jersey, United States
Hudson Valley Cancer Center
Fishkill, New York, United States
SUNY Upstate Medical University
Syracuse, New York, United States
East Carolina School of Medicine
Greenville, North Carolina, United States
Aultman Medical Group Hematology & Oncology
Canton, Ohio, United States
University of Cincinnati Cancer Institute
Cincinnati, Ohio, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
The James Cancer Hospital
Columbus, Ohio, United States
UPMC Hillman Cancer Center
Greenville, Pennsylvania, United States
Steward Sharon Regional Cancer Center
Hermitage, Pennsylvania, United States
UPMC Hillman Cancer Center
New Castle, Pennsylvania, United States
Abramson Cancer Center at Pennsylvania Hospital
Philadelphia, Pennsylvania, United States
The West Clinic
Germantown, Tennessee, United States
Tennessee Oncology PLLC
Hixson, Tennessee, United States
UVAHS Emily Couric Clin Cancer Ctr
Charlottesville, Virginia, United States
Kaiser Permanente of WA
Olympia, Washington, United States
Harrison HealthPartners Hematology
Poulsbo, Washington, United States
Seattle Integrative Cancer Center
Renton, Washington, United States
Mon Health Medical Center
Morgantown, West Virginia, United States
SSM Health Cancer Care Center
Madison, Wisconsin, United States
West Allis Memorial Hospital
West Allis, Wisconsin, United States
Ordensklinikum Linz GmbH Elisabethinen
Linz, Upper Austria, Austria
Kepler Universitätsklinikum GmbH, Med Campus III
Linz, Upper Austria, Austria
CLION - Clínica de Oncologia
Salvador, Estado de Bahia, Brazil
Instituto Londrina de Radioterapia
Londrina, Paraná, Brazil
CHUM
Montreal, Quebec, Canada
Allan Blair Cancer Centre
Regina, Saskatchewan, Canada
Szabolcs-Szatmár-Bereg Megyei Kórházak és Egyetemi Oktatókórház, Jósa András Oktatókórház
Nyíregyháza, Szabolcs-Szatmár-Bereg, Hungary
National Institute of Oncology
Budapest, , Hungary
Healthcare Global Enterprises Limited (HCG)
Bangalore, Karnataka, India
Istituto Oncologico Veneto IRCCS
Padua, Veneto, Italy
IRCCS - AOU di Bologna
Bologna, , Italy
Ospedale Santa Chiara di Trento
Trento, , Italy
Gachon University Gil Medical Center
Namdong-gu, Incheon, South Korea
Inha University Hospital
Incheon, Incheon-gwangyeoksi [Incheon], South Korea
Seoul National University Bundang Hospital
Seongnam, Kyǒnggi-do, South Korea
Pusan National University Hospital
Busan, Pusan-Kwangyǒkshi, South Korea
Wonkwang University Hospital
Iksan-si, Jeonlabuk-do, , South Korea
Hospital Universitario de Canarias
Santa Cruz de Tenerife, La Laguna, Spain
Hospital De Navarra
Pamplona, Navarre, Spain
Clínica Mompia
Cantabria, Santa Cruz de Bezana, Spain
Hospital Universitari Vall d'Hebron
Barcelona, , Spain
Cl. Universitaria Navarra
Madrid, , Spain
Centro Oncológico MD Anderson
Madrid, , Spain
Hospital Clinico San Carlos
Madrid, , Spain
Hospital Madrid Norte Sanchinarro
Madrid, , Spain
Gerencia de Asistencia Sanitaria de Segovia_Hospital General de Segovia
Segovia, , Spain
Hospital Universitario Virgen Del Rocio
Seville, , Spain
Fundación Instituto Valenciano de Oncología
Valencia, , Spain
Hospital Universitario La Fe de Valencia
Valencia, , Spain
China Medical University Hospital
Taichung, , Taiwan
The Christie NHS Foundation Trust
Manchester, Greater Manchester, United Kingdom
Ninewells Hospital
Dundee, Scotland, United Kingdom
Queen Elizabeth Hospital Birmingham
Birmingham, , United Kingdom
Cambridge University Hospitals NHS Foundation Trust
Cambridge, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
I5B-MC-Y001
Identifier Type: OTHER
Identifier Source: secondary_id
17468
Identifier Type: -
Identifier Source: org_study_id